NEW YORK, March 1, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Actavis, Inc. (NYSE: ACT), AstraZeneca PLC (NYSE: AZN), Bristol-Myers Squibb Company (NYSE: BMY), Gilead Sciences Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: NVO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Actavis, Inc. Research Report
The US Food and Drug Administration (FDA) recently approved Actavis' generic Suboxone for maintenance treatment of opioid dependence. According to IMS Health Data, total sales for Actavis Suboxone reached $625 million for full-year 2012, and it is expected to surge in revenues after the approval. Drug dependence is a common problem in various regions, and Actavis' generic Suboxone may possibly rake in a great market share in the global market. Actavis reported net revenue increase of 13% to $1.75 billion during the fourth quarter and 29% to $5.9 billion for full-year 2012. The Full Research Report on Actavis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/d9b4_ACT]
AstraZeneca PLC Research Report
Investors are looking forward to AstraZeneca's Capital Markets Day on March 21, 2013 when the company announces its new strategy amid the challenges caused by global market conditions. AstraZeneca remains positive after receiving high-level results from KODIAC-08, a 52-week-long safety trial for Naloxegol versus usual care. The core PhaseIII programme is now completed, and AstraZeneca is advancing Naloxegol for regulatory submission within the year. Naloxegol is used for the treatment of opioid-pain-medicine-related constipation, and is a product under the exclusive worldwide license agreement between AstraZeneca and Nektar Therapeutics. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/8c20_AZN]
Bristol-Myers Squibb Company Research Report
The collaboration agreement between Bristol-Myers and Reckitt Benckiser allows the former to easily penetrate Latin America through the distribution and marketing of several over-the-counter medicines. Bristol-Myers will receive $438 million from Reckitt Benckiser apart from royalties on product sales during its collaboration term. Brazil and Mexico, both emerging markets, are the primary segments where these several products will circulate. According to an official press release from Bristol-Myers, the company's biopharma strategy allows the company to focus on providing innovative medicines in areas of high unmet medical need. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4a88_BMY ]
Gilead Sciences Inc. Research Report
Despite Gilead's leadership in HIV/AIDS treatments, the company's acquisition of YM BioSciences Inc. is a foolproof reason for analysts and investors to be bullish about the company. The company's long-term growth looks promising as it continues to boost its portfolio with smart acquisitions. Gilead raked in 17.6% revenue growth to $2.59 billion during the fourth quarter. Analysts are expecting Gilead to post better revenues as soon as it utilizes cancer treatments that are reported to have a great market. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/5969_GILD]
Novo Nordisk A/S Research Report
Novo Nordisk, a global healthcare company with 90 years of innovation and leadership in diabetes care, recently launched NovoSeven with pre-filled syringe for fast bleeding control. NovoSeven is a support rapid treatment for haemophilia patients with inhibitors. Novo Nordisk already received approvals for NovoSeven from European Medicines Agency (EMA) and US Food and Drug Administration (FDA). The company's Tresiba, a once-daily basal insulin, is also ready for release in Japan. Analysts are expecting Novo Nordisk to penetrate more markets in the coming quarters. The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4e4f_NVO]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers Email: email@example.com Main: +1-(480)-745-7826